ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc. (ALZN) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (C-). The rating has held at C+ for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B+ (3.7) | C- (2.1) | C (2.2) | C+ (2.8) | C+ (2.6) | C+ (2.7) |
| 2026-11-10 | A- (3.9) | C- (2.1) | C (2.2) | B- (3.0) | C+ (2.6) | C+ (2.8) |
| 2026-11-03 | B+ (3.7) | C- (2.1) | C (2.3) | C+ (2.8) | C+ (2.7) | C+ (2.7) |
| 2026-10-27 | B+ (3.7) | C- (2.1) | C (2.4) | B (3.2) | C+ (2.6) | C+ (2.8) |
| 2026-10-20 | B+ (3.7) | C- (2.1) | C (2.3) | B (3.4) | C+ (2.6) | C+ (2.8) |